Palisade Bio Inc (PALI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Palisade Bio Inc stock (PALI) is currently trading at $2.00. Palisade Bio Inc PS ratio (Price-to-Sales) is 14.03. Analyst consensus price target for PALI is $12.00. WallStSmart rates PALI as Sell.
- PALI PE ratio analysis and historical PE chart
- PALI PS ratio (Price-to-Sales) history and trend
- PALI intrinsic value — DCF, Graham Number, EPV models
- PALI stock price prediction 2025 2026 2027 2028 2029 2030
- PALI fair value vs current price
- PALI insider transactions and insider buying
- Is PALI undervalued or overvalued?
- Palisade Bio Inc financial analysis — revenue, earnings, cash flow
- PALI Piotroski F-Score and Altman Z-Score
- PALI analyst price target and Smart Rating
Palisade Bio Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Palisade Bio Inc (PALI) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Palisade Bio Inc (PALI) Key Strengths (1)
91.81% of shares held by major funds and institutions
Supporting Valuation Data
Palisade Bio Inc (PALI) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 14.0x annual revenue
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Supporting Valuation Data
Palisade Bio Inc (PALI) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 1 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Market Cap. Some valuation metrics including Price/Sales (14.03), Price/Book (2.19) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -228.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -228.60% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PALI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PALI's Price-to-Sales ratio of 14.03x trades at a deep discount to its historical average of 1798.95x (0th percentile). The current valuation is 100% below its historical high of 9698.42x set in Dec 2020, and 0% above its historical low of 14.03x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~410.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Palisade Bio Inc (PALI) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Palisade Bio Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.07 indicates a conservative balance sheet with 5M in cash.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.55, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Palisade Bio Inc.
Bottom Line
Palisade Bio Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Palisade Bio Inc(PALI)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. The company is headquartered in Carlsbad, California.